Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Gastroenterology. 2017 Dec 8;154(5):1380–1390.e5. doi: 10.1053/j.gastro.2017.12.001

Table 4.

Association between regular aspirin and non-aspirin NSAID use and incident pancreatic cancer stratified by diabetes status.

Aspirin* Non-aspirin NSAIDs*
Diabetes Status Nonregular users Regular users Pinteraction Nonregular users Regular users Pinteraction
Diabetes 0.05 0.91
No
 No. cases 483 427 570 224
 Person-years 2,332,301 1,566,450 1,964,554 810,961
 Age-adjusted RR (95% CI) 1 1.03 (0.90, 1.17) 1 0.99 (0.84, 1.16)
 Multivariable RR (95% CI)§ 1 1.01 (0.89, 1.16) 1 1.03 (0.88, 1.21)
Yes
 No. cases 110 102 143 57
 Person-years 153,227 162,786 183,406 86,047
 Age-adjusted RR (95% CI) 1 0.75 (0.57, 1.00) 1 0.97 (0.71, 1.34)
 Multivariable RR (95% CI)§ 1 0.71 (0.54, 0.94) 1 1.02 (0.74, 1.41)

CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs; RR, relative risk

*

Current exposure, aspirin and non-aspirin NSAID use obtained from the most recent questionnaire cycle.

§

Multivariate models conditioning on age (months) and questionnaire cycle and adjusted for sex/cohort, race (White, Black, other, unknown), BMI in kg/m2 (<25.0, 25.0–29.9, 30.0–34.9, ≥35.0, missing), smoking in pack-years (never, <5, 5–19, 20–39, ≥40, missing), alcohol intake in grams/day (0, 0.1–4.9, 5.0–14.9, 15.0–29.9, ≥30.0, missing), multivitamin use (yes/no), physical activity (quintiles by sex), and regular use of aspirin (yes/no) or non-aspirin NSAID (yes/no/missing) depending on the primary exposure.

Tests for interaction performed by entering into the model a cross-product term of regular aspirin or non-aspirin NSAID use (yes/no) and diabetes mellitus (yes/no).